BioCentury | May 26, 2008
Finance

Late-stage opportunities

...Genmab (CSE:GEN) -37% ImmuPharma (LSE:IMM) -42% Newron (SWX:NWRN) -36% Galapagos (Euronext:GLPG) -40% Jerini (Xetra:JI4) -33% Henderson Morley...
BioCentury | Mar 31, 2008
Company News

Henderson Morley, Australian Centre for Vaccine Development deal

...EBV) using the center's EBV polyepitope antigen incorporated into Henderson Morley's PREPS and L-particles delivery vector. Henderson Morley...
...Both parties will fund development and jointly own resulting IP. Further terms were not disclosed. Henderson Morley plc...
BioCentury | Jan 15, 2007
Finance

Ebb & Flow

...agreed to co-develop and commercialize BINV's antibody candidate, BI-204 , to treat multiple cardiovascular conditions. Henderson Morley...
BioCentury | Sep 4, 2006
Finance

Ebb & Flow

...results and reported that Cantor Fitzgerald Europe holds 25.5 million shares (5.5%) of the company. Henderson Morley...
BioCentury | Aug 7, 2006
Finance

Ebb & Flow

...its stake. The company's shares fell from 10.25p last Tuesday to close Friday at 6.25p. Henderson Morley...
BioCentury | Jun 26, 2006
Finance

Ebb & Flow

...five years. EVT will be eligible for milestones that could exceed e100 million, plus royalties. Henderson Morley...
BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...up front and is eligible for about E36 million ($43.6 million) in milestones (see B4). Henderson Morley...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

...The company's Imvamune third-generation Modified Virus Ankara (MVA) smallpox vaccine is in Phase II trials. Henderson Morley...
Items per page:
1 - 8 of 8
BioCentury | May 26, 2008
Finance

Late-stage opportunities

...Genmab (CSE:GEN) -37% ImmuPharma (LSE:IMM) -42% Newron (SWX:NWRN) -36% Galapagos (Euronext:GLPG) -40% Jerini (Xetra:JI4) -33% Henderson Morley...
BioCentury | Mar 31, 2008
Company News

Henderson Morley, Australian Centre for Vaccine Development deal

...EBV) using the center's EBV polyepitope antigen incorporated into Henderson Morley's PREPS and L-particles delivery vector. Henderson Morley...
...Both parties will fund development and jointly own resulting IP. Further terms were not disclosed. Henderson Morley plc...
BioCentury | Jan 15, 2007
Finance

Ebb & Flow

...agreed to co-develop and commercialize BINV's antibody candidate, BI-204 , to treat multiple cardiovascular conditions. Henderson Morley...
BioCentury | Sep 4, 2006
Finance

Ebb & Flow

...results and reported that Cantor Fitzgerald Europe holds 25.5 million shares (5.5%) of the company. Henderson Morley...
BioCentury | Aug 7, 2006
Finance

Ebb & Flow

...its stake. The company's shares fell from 10.25p last Tuesday to close Friday at 6.25p. Henderson Morley...
BioCentury | Jun 26, 2006
Finance

Ebb & Flow

...five years. EVT will be eligible for milestones that could exceed e100 million, plus royalties. Henderson Morley...
BioCentury | Apr 10, 2006
Finance

Ebb & Flow

...up front and is eligible for about E36 million ($43.6 million) in milestones (see B4). Henderson Morley...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

...The company's Imvamune third-generation Modified Virus Ankara (MVA) smallpox vaccine is in Phase II trials. Henderson Morley...
Items per page:
1 - 8 of 8